Q3’25 Psychedelic Lobbying Update
Each quarter, we provide a look at federal lobbying disclosures by psychedelic drug developers and nonprofits. That data is a lagging indicator, especially as filings are not required immediately at the end of each quarter.
The data is available via our Psychedelics Federal Lobbying Tracker. Below is our analysis of the latest developments for our Pα+ subscribers. Here’s a review of Q3 2025 activity…
Drug Developers’ Federal Lobbying Spend Reaches New High
In aggregate, federal lobbying spend among psychedelic drug developers has reached a new high in Q3’25, with a modest increase over previous quarters this year.
That record comes in spite of Lykos Therapeutics’ decision to terminate its federal lobbying spend, according to filings. Over the past two years, Lykos had been the biggest spender on such efforts, which was unsurprising given that it was the first developer to attempt to score FDA approval...
Join Today
Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and research.
- Regular Bulletins featuring news, analysis, and research
- Articles and deep dives across psychedelic drug development, policy, and research
- Exclusive interviews with researchers, executives, and policymakers
- Bespoke resources and tools including the Psychedelic Bill Tracker
- Quarterly video briefings and slide decks